EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sclareol protected against intestinal barrier dysfunction ameliorating Crohn's disease-like colitis via Nrf2/NF-B/MLCK signalling

Lian Wang, Xue Song, Yueqing Zhou, Yongsheng Xia, Zi Yang, Xiaohua Chen, Ruohan Shi, Zhijun Geng, Xiaofeng Zhang, Yueyue Wang, Jing Li, Jianguo Hu und 1 weitere

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Lian Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China; Anhui Province Key Laboratory o…. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Crohn Disease, Signal Transduction, NF-kappa B. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inflammation-induced intestinal barrier dysfunction is not only a pathological feature of Crohn's disease (CD) but also an important therapeutic target. Sclareol (SCL) is a nontoxic natural plant compound with anti-inflammatory effect, but its role in CD has not been established. METHODS: In vivo studies of mice with TNBS-induced colitis were carried out to evaluate the effects of SCL on CD-like colitis and intestinal barrier function. In vitro, a TNF-α-induced colonic organoid model was established to test the direct effect of SCL on inflammation-induced intestinal barrier injure and inflammatory response. The Nrf2/NF-κB/MLCK signalling was analysed to explore the mechanism of SCL. RESULTS: In vivo, SCL largely alleviated the colitis in TNBS mice, as evidenced by improvements in the weight loss, colitis symptoms, endoscopic score, macroscopic histological score, and histological inflammation score. Moreover, SCL significantly improved intestinal barrier dysfunction, manifested as reduced intestinal permeability and decreased intestinal bacterial translocation in TNBS mice. Importantly, SCL antagonised the intestinal mucosal inflammation while protecting tight junctions in TNBS mice. In vitro, SCL largely depressed pro-inflammatory cytokines levels and improved intestinal epithelial permeability in a TNF-α-induced colonic organoid model. In the context of CD, the protective effects of SCL against inflammation and intestinal barrier damage are at least partially results from the Nrf2 signalling activation and the NF-κB/MLCK signalling inhibition. CONCLUSIONS: SCL improved intestinal barrier dysfunction and alleviated CD-like colitis, possibly through modulation of Nrf2/NF-κB/MLCK signalling. In view of SCL's safety profile, there is hope that it will be useful in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2Crohn DiseaseSignal TransductionNF-kappa BColitisIntestinal MucosaTrinitrobenzenesulfonic AcidAnimalsMiceHumansMaleDisease Models, AnimalAnti-Inflammatory AgentsMyosin-Light-Chain KinaseMice, Inbred C57BLPermeabilityColonDiterpenesTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Colonic organoidsCrohn's diseaseIntestinal barrier functionPhytopharmaceuticalSclareol

Substanzen

NF-E2-Related Factor 2NF-kappa BNfe2l2 protein, mouseTrinitrobenzenesulfonic AcidAnti-Inflammatory AgentsMyosin-Light-Chain KinaseDiterpenesTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China; Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, B…
  • Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu, Anhui, China.
  • Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu, Anhui, China. Electronic address: jghu9200@bbmc.edu.cn.

Zitieren

APA

Wang, L., Song, X., Zhou, Y., Xia, Y., Yang, Z., Chen, X., Shi, R., Geng, Z., Zhang, X., Wang, Y., Li, J., Hu, J., & Zuo, L. (2024). Sclareol protected against intestinal barrier dysfunction ameliorating Crohn's disease-like colitis via Nrf2/NF-B/MLCK signalling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112140

Vancouver

Wang L, Song X, Zhou Y, Xia Y, Yang Z, Chen X, et al. Sclareol protected against intestinal barrier dysfunction ameliorating Crohn's disease-like colitis via Nrf2/NF-B/MLCK signalling. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112140

BibTeX
@article{Wang2024,
  author = {Wang, Lian and Song, Xue and Zhou, Yueqing and Xia, Yongsheng and Yang, Zi and Chen, Xiaohua and Shi, Ruohan and Geng, Zhijun and Zhang, Xiaofeng and Wang, Yueyue and Li, Jing and Hu, Jianguo and Zuo, Lugen},
  title = {Sclareol protected against intestinal barrier dysfunction ameliorating Crohn's disease-like colitis via Nrf2/NF-B/MLCK signalling},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112140}
}
Kostenlos starten →